Evaluation of Dupilumab in Patients With Bullous Pemphigoid.

ABSTRACT:

Importance

Dupilumab is a theoretically novel therapy for bullous pemphigoid (BP). However, its effectiveness and safety have yet to be confirmed in a large-scale study.

Objective

To assess the efficacy and safety of dupilumab in patients with BP and evaluate factors that potentially affect short-term and long-term outcomes.

Design, setting, and participants

A retrospective cohort study was conducted from January 1, 2021, to July 31, 2022. The median (IQR) follow-up period was 24.6 (11.5-38.4) weeks. This multicenter study was performed in 6 dermatology departments of the National Autoimmune Bullous Diseases Cooperative Group of China. Adult patients with BP that received 300 mg of dupilumab every 2 weeks following an initial dose of 600 mg were included. Patients wer

SUBMITTER: Zhao L 

PROVIDER: S-EPMC10398542 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature